Avadel Pharmaceuticals Files 8-K
| Field | Detail |
|---|---|
| Company | Avadel Pharmaceuticals PLC |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Avadel Pharma filed an 8-K on Dec 18, 2025, with financial and other disclosures.
AI Summary
Avadel Pharmaceuticals plc filed an 8-K on December 18, 2025, reporting on financial statements and exhibits. The filing also includes information related to Regulation FD disclosure and other events. Avadel Pharmaceuticals plc is incorporated in Ireland and its principal executive offices are located in Dublin.
Why It Matters
This 8-K filing provides important updates and disclosures from Avadel Pharmaceuticals plc to the SEC, which are crucial for investors to understand the company's current status and any material events.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not appear to contain any immediate negative or positive material events.
Key Players & Entities
- Avadel Pharmaceuticals plc (company) — Registrant
- December 18, 2025 (date) — Date of earliest event reported
- Ireland (location) — State or other jurisdiction of incorporation
- Dublin (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a current report pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, covering financial statements, exhibits, Regulation FD disclosures, and other events.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 18, 2025.
In which jurisdiction is Avadel Pharmaceuticals plc incorporated?
Avadel Pharmaceuticals plc is incorporated in Ireland.
What is the address of Avadel Pharmaceuticals plc's principal executive offices?
The principal executive offices of Avadel Pharmaceuticals plc are located at 10 Earlsfort Terrace, Dublin 2, Ireland, D02 T380.
What is the SEC file number for Avadel Pharmaceuticals plc?
The SEC file number for Avadel Pharmaceuticals plc is 001-37977.
Filing Stats: 871 words · 3 min read · ~3 pages · Grade level 13.3 · Accepted 2025-12-18 07:08:28
Key Financial Figures
- $0.01 — stered Ordinary Shares, nominal value $0.01 per share AVDL The Nasdaq Global Ma
Filing Documents
- tm2533819d1_8k.htm (8-K) — 30KB
- tm2533819d1_ex99-1.htm (EX-99.1) — 27KB
- tm2533819d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-25-122274.txt ( ) — 233KB
- avdl-20251218.xsd (EX-101.SCH) — 3KB
- avdl-20251218_lab.xml (EX-101.LAB) — 33KB
- avdl-20251218_pre.xml (EX-101.PRE) — 22KB
- tm2533819d1_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On December 18, 2025, Avadel Pharmaceuticals plc (the "Company") issued a press release titled "Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ Trial in Idiopathic Hypersomnia." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01
Item 8.01 Other Events. On December 18, 2025, the Company announced that the Company completed enrollment in REVITALYZ, a Phase 3 study evaluating LUMRYZ TM as a potential treatment for idiopathic hypersomnia. The Company expects data from REVITALYZ in the second quarter of 2026. Cautionary Disclosure Regarding Forward-Looking Statements This Current Report on Form 8-K includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects or other events. Such forward-looking statements include, but are not limited to, statements regarding the Company's expectations for data from REVITALYZ in the second quarter of 2026. In some cases, forward-looking statements can be identified by the use of words such as "will," "may," "could," "believe," "expect," "look forward," "on track," "guidance," "anticipate," "estimate," "project," "next steps" and similar expressions and the negatives thereof (if applicable). The Company's forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, the Company's business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of the company's business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in the Company's forward-looking statements include the risks and uncertainties described in the "Risk Factors" section of Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange
01 Exhibits
Item 9.01 Exhibits. (d) Exhibits 99.1 Press release issued by Avadel Pharmaceuticals plc on December 18, 2025, furnished herewith. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 18, 2025 AVADEL PHARMACEUTICALS PLC By: /s/ Jerad G. Seurer Name: Jerad G. Seurer Title: General Counsel & Corporate Secretary